Duke University Health System Launches OneDukeGen
In a new precision medicine study, genomic and health data will be collected to understand connections between genetics, health, and disease.
The Duke University Health System and School of Medicine, in partnership with nference, an AI-enabled software platform provider, are launching OneDukeGen. The aim of this precision medicine study is to advance healthcare by integrating comprehensive genomic data and health information toward understanding hereditary disease susceptibilities.
Led by principal investigator Svati Shah, MD, MHS, Associate Dean of Genomics, the study hopes to recruit over 100,000 consented Duke patients. The study is designed to ensure a diverse representation of populations, and was informed through input from community groups. The study will also offer return of genetic sequencing results from the research.
The collaborators stated in a release that Duke researchers and clinicians who will work in tandem to integrate research findings into patient care, and hopes to bridge the gap between scientific discovery and clinical practice.
Learn more about the OneDukeGen study and how Duke patients will be invited to participate.
Reference: “Duke University Health System Launches OneDukeGen, a New Precision Medicine Study,” August 15, 2023. Duke University School of Medicine.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
